A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-ass
IMI/REL met noninferiority criteria vs PIP/TAZ for 28-day ACM, and safety profiles were comparable. This trial could support the use of IMI/REL to treat adults with HABP/VABP, including regional use in China.
Authors
- Xiaoling Du (ORCID: https://orcid.org/0000-0001-7857-1688)
- Wei Feng (ORCID: https://orcid.org/0000-0001-6997-926X)
- Xiang Peng (ORCID: https://orcid.org/0000-0003-3453-4062)
- Sandra Koseoglu (ORCID: https://orcid.org/0000-0002-2209-5288)
- Fang Sun (ORCID: https://orcid.org/0000-0003-2892-6553)
- Mingfen Zhu
- Katherine Young (ORCID: https://orcid.org/0000-0002-1490-5455)
- Min Zhou (ORCID: https://orcid.org/0000-0002-8718-8506)
- Luke Francis Chen
- Christopher Bruno (ORCID: https://orcid.org/0000-0003-2056-7170)
- Xiaodan Guo (ORCID: https://orcid.org/0000-0002-9876-9445)
- Zlatka Iamboliyska
- Junjie Li (ORCID: https://orcid.org/0000-0002-8266-5094)
- Lianshu Ding (ORCID: https://orcid.org/0000-0001-5412-5069)
- Jieming Qu (ORCID: https://orcid.org/0000-0003-4517-9473)
- Zhengang Tang (ORCID: https://orcid.org/0000-0001-9160-2565)
- María Falk de Losada
- Chang Chen
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Hubei University of Medicine (CN)
- Ruijin Hospital (CN)
- Changsha Central Hospital (CN)
- First People's Hospital of Nanning (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1016/j.ijid.2024.107357
- Citations
- 3
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.16